Open Access<p>Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study</p>
Author(s) -
Jialyu Huang,
Qin Xie,
Jiaying Lin,
Xuefeng Lü,
Jing Zhu,
Hongyuan Gao,
Renfei Cai
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s230129
Subject(s) - dydrogesterone , medroxyprogesterone acetate , progestin , medicine , in vitro fertilisation , gynecology , andrology , medroxyprogesterone , estrogen , biology , pregnancy , genetics
Dydrogesterone (DYG) is an alternative progestin in progestin-primed ovarian stimulation (PPOS) protocol with weaker pituitary suppression than medroxyprogesterone acetate (MPA) in normal ovulatory women. However, the endocrinological characteristics, oocyte retrieval and pregnancy outcomes of DYG application in polycystic ovarian syndrome (PCOS) patients undergoing in vitro fertilization (IVF) remain unclear.